Limitations in thrombolytic therapy in acute ischemic stroke

Pakistan Journal of Medical Sciences

Volumn 28, Issue 4, 2012, Pages 586-590

  Kocak, Sedat ^b   Dogan, Emine ^a   Kokcam, Melek ^b   Girisgin, Abdullah Sadik ^b   Bodur, Said ^b  

^a Emergency Department   (Turkey)

^b NECMETTIN ERBAKAN UNIVERSITY   (Turkey)

Author keywords

Acute; Stroke; Thrombolytic therapy

Indexed keywords

FIBRINOLYTIC AGENT; GLUCOSE;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DISEASE COURSE; EMERGENCY WARD; FEMALE; FIBRINOLYTIC THERAPY; FRACTURE; GASTROINTESTINAL HEMORRHAGE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MAJOR SURGERY; MALE; MULTILOBAR INFARCT; NEUROLOGIC DISEASE; PROSPECTIVE STUDY; SEIZURE; SUBARACHNOID HEMORRHAGE; TIME; TREATMENT CONTRAINDICATION; URINARY TRACT HEMORRHAGE;

EID: 84865164930     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Reeves MJ, Arora S, Broderick JP, Frankel M, Heinrich JP, Hickenbottom S, et al. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke 2005;36(6):1232-1240.
2. Saposnik G, Black SE, Hakim A, Fang J, Tu JV, Kapral MK. Age disparities in stroke quality of care and delivery of health services. Stroke 2009;40(10):3328-3335.
3. Hills NK, Johnston SC. Why are eligible thrombolysis candidates left untreated? Am J Prev Med 2006;31(6 Suppl 2):S210-216.
4. NIH Stroke Scale. http://www.ninds.nih.gov/doctors/NIH_Stroke_Scale.pdf Accessed Dec 01, 2010.
5. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early management of adults with ischemic stroke. Circulation 2007;115(20):e478-534.
6. Jones SP, Jenkinson AJ, Leathley MJ, Watkins CL. Stroke knowledge and awareness: an integrative review of the evidence. Age Ageing 2010;39(1):11-22.
7. Kothari R, Jauch E, Broderick J, Brott T, Sauerbeck L, Khoury J, et al. Acute stroke: delays to presentation and emergency department evaluation. Ann Emerg Med 1999;33(1):3-8.
8. Schwamm LH, Reeves MJ, Pan W, Smith EE, Frankel MR, Olson D, et al. Race/ethnicity, quality of care, and outcomes in ischemic stroke. Circulation 2010;121(13):1492-1501.
9. Kwan J, Hand P, Sandercock P. A systematic review of barriers to delivery of thrombolysis for acute stroke. Age Ageing 2004;33(2):116-121.
10. Maestroni A, Mandelli C, Manganaro D, Zecca B, Rossi P, Monzani V, et al. Factors infuencing delay in presentation for acute stroke in an emergency department in Milan, Italy. Emerg Med J 2008;25(6):340-345.
11. Chang KC, Tseng MC, Tan TY. Prehospital delay after acute stroke in Kaohsiung, Taiwan. Stroke 2004;35(3):700-704.
12. Keskin O, Kalemoglu M, Ulusoy RE. A clinic investigation into prehospital and emergency department delays in acute stroke care. Med Princ Pract 2005;14(6):408-412.
13. Naganuma M, Toyoda K, Nonogi H, Yokota C, Koga M, Yokoyama H, et al. Early hospital arrival improves outcome at discharge in ischemic but not hemorrhagic stroke: a prospective multicenter study. Cerebrovasc Dis 2009;28(1):33-38.
14. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363(9411):768-774.
15. García-Moncó JC, Pinedo A, Escalza I, Ferreira E, Foncea N, Gómez-Beldarrain M, et al. Analysis of the reasons for exclusion from tPA therapy after early arrival in acute stroke patients. Clin Neurol Neurosurg 2007;109(1):50-53.
16. O'Connor RE, McGraw P, Edelsohn L. Thrombolytic therapy for acute ischemic stroke: why the majority of patients remain ineligible for treatment. Ann Emerg Med 1999;33(1):9-14.
17. Qureshi AI, Kirmani JF, Sayed MA, Safdar A, Ahmed S, Ferguson R, et al. Time to hospital arrival, use of thrombolytics, and in-hospital outcomes in ischemic stroke. Neurology 2005;64(12):2115-2120.
18. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset The ATLANTIS Study: A Randomized Controlled Trial. JAMA 1999;282:2019-2026.
19. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359(13):1317-1329.
20. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375(9727):1695-1703.
21. Kim YS, Park SS, Bae HJ, Cho AH, Cho YJ, Han MK, et al. Stroke awareness decreases prehospital delay after acute ischemic stroke in Korea. BMC Neurol 2011;11:2.
22. De Keyser J, Gdovinová Z, Uyttenboogaart M, Vroomen PC, Luijckx GJ. Intravenous alteplase for stroke: beyond the guidelines and in particular clinical situations. Stroke 2007;38(9):2612-2618.